Carbonic anhydrase IX (CAIX) is a hypoxia-regulated and tumor-specific protein that maintains the pH balance of cells. Targeting CAIX might be a valuable approach for specific delivery of cytotoxic drugs, thereby reducing normal tissue side-effects. A series of dual-target compounds were designed and synthesized incorporating a sulfonamide, sulfamide, or sulfamate moiety combined with several different anti-cancer drugs, including the chemotherapeutic agents chlorambucil, tirapazamine, and temozolomide, two Ataxia Telangiectasia and Rad3-related protein inhibitors (ATRi), and the antidiabetic biguanide agent phenformin. An ATRi derivative (12) was the only compound to show a preferred efficacy in CAIX overexpressing cells versus cells without CAIX expression when combined with radiation. Its efficacy might however not solely depend on binding to CAIX, since all described compounds generally display low activity as carbonic anhydrase inhibitors. The hypothesis that dualtarget compounds specifically target CAIX expressing tumor cells was therefore not confirmed. Even though dual-target compounds remain an interesting approach, alternative options should also be investigated as novel treatment strategies.
Introduction
Solid tumors are characterized by a hypoxic microenvironment caused by their immature and inadequate vascular supply of oxygen and nutrients. These hostile hypoxic conditions result in a phenotype that is associated with a worse prognosis [1] and resistance to standard treatment options such as radiotherapy, chemotherapy, and surgery [2] [3] , and [4] . Several different approaches are currently being investigated to target these hypoxic areas to make tumors more sensitive to standard treatment modalities [5] [6] , and [7] .
Carbonic anhydrase IX (CAIX) can be a valuable therapeutic target since it plays an important role in maintaining the intracellular pH homeostasis [8] and [9] . Furthermore its expression is predominantly tumor specific [5] [8] , and [10] and directly regulated via the hypoxia-inducible factor (HIF) pathway [11] . Even though alternative pathways are also able to modulate CAIX expression [12] [13] , and [14] , its significant prognostic value in many different tumor types [15] has promoted investigations in its use as an imaging agent for diagnostic and prognostic purposes [5] [ 16] , [17] [18] , and [19] . Together these characteristics of CAIX support investigations into the therapeutic targeting of CAIX to improve efficacy of standard treatments. The function of CAIX is evolutionary conserved and catalyzes the hydration of carbon dioxide to bicarbonate at the cell membrane. The bicarbonate is transported back intracellular from the extracellular space, whereas the free proton is extruded in the extracellular space. CAIX thereby maintains the balance between an acidic extracellular and alkaline intracellular pH of tumor cells, the latter of which would otherwise acidify due to the increased acid production resulting from their glycolytic metabolism [8] and [9] . Many different inhibitors are currently being developed to specifically target the tumor-associated CAIX isoform and have shown promise in reducing tumor cell survival, migration, invasion, and reduce tumor xenograft growth and metastases formation [20] [21] , [22] , and [23] . Furthermore, the combination therapy of CAIX inhibitors (CAIXi) with standard treatment options was previously found to increase the efficacy of radiotherapy [24] and of weakly basic chemotherapeutic agents such as doxorubicin [25] .
The predominant expression of CAIX on hypoxic tumor cells can also be exploited to direct cytotoxic agents specifically to those CAIX expressing cancer cells thereby possibly minimizing normal tissue toxicity. This can be achieved by conjugating anti-cancer drugs with CAIX inhibiting molecules that bind to the Zn 2þ active site of CAIX and hence inhibit its enzymatic function [8] [26] , and [27] , i.e. a so-called dual-targeting approach. Our group showed previously that such a dual-target approach with a sulfamide CAIXi moiety coupled to the radiosensitizing compound nitroimidazole to be a more effective radiosensitizer than an indanesulfonamide CAIXi [28] . Alternative novel dual-target compounds have been developed to investigate this strategy of dual-targeting further in the context of anti-cancer agents to target CAIX. Here we have designed five different classes of dual-target compounds conjugated to CAIXi (sulfonamide, sulfamide, or sulfamate), which included the chemotherapeutic anti-cancer agents chlorambucil, tirapazamine, and temozolomide, two ataxia telangiectasia and Rad3-related protein inhibitors (ATRi), and the biguanide agent phenformin, previously used in diabetes treatment. We hypothesize that these new dual-target compounds will have the ability to specifically target CAIX expressing cells and modulate their efficacy in a CAIX-dependent manner.
Results and discussion

Chemistry
Chlorambucil was converted to its acid chloride [29] 1 by using oxalyl chloride. This chlorambucil acid chloride reacted with different benzene sulfonamides under basic condition to obtain good yields of chlorambucil derivatives 2a, 2b and 2c. Chlorambucil carbamate derivatives were obtained by converting compound 1 into a methyl ester [30] using methanol. This ester was reduced to alcohol [31] , i.e. compound 3, after treating with lithium aluminium hydride. Compound 3 was treated with triphosgene to obtain its respective chloroformate [32] , i.e. compound 4 (Scheme 2). The reaction of chlorambucil chloroformate (4) with different benzene sulfonamides resulted in compounds 5a, 5b and 5c (Scheme 3).
Tirapazamine derivatives 8 and 11 were synthesized from 6 and 9 with the previously described procedure [33] . In short, 6 and 9 reacted with 4-(2-aminoethyl) benzene sulfonamide under reflux conditions and was followed by oxidation of the mono-oxides (Scheme 4).
The ATRi derivatives 12 and 13 were synthesized from commercially available VE-821 and VE-822 (MedChemTronica) using a classical synthetic strategy described previously [25] (Scheme 5).
Commercially purchased temozolomide (SelleckChem) was converted into its respective acid by treating with concentrated sulfuric acid and sodium nitrate at 0 Ce15 C (Scheme 6) [34] . Reacting the temozolomic acid with different benzenesulfonamides, aminoxysulfonamide [35] and 5-amino-1, 3,4-thiadiazole-2sulfonamide hydrochloride under known amide bond formation conditions [34] resulted in compounds 15a, 15b, 15c and 15d (Scheme 7).
The compound 18 was obtained by a slight modification based on the method reported by Kelarev et al. [36] . The commercially available compounds 4-(2-aminoethyl) benzenesulfonamide 16
and cyanoguanidine 17 were coupled in n-butanol using a stoichiometric amount of hydrochloric acid (Scheme 8).
Binding affinity human CAs
Increased binding affinity to human carbonic anhydrases (CAs) as compared with their respective parental compound are observed ( Table 1) for most of the compounds, except for the CAIXi conjugated ATRi (12 and 13), which do not bind to any of the four tested human CA isoforms included (K i > 50000 nM). The K i values of the other dual-targeting compounds are higher than of the previously reported CAIXi [20] with 15a showing relatively good K i for the CAII and CAIX isoforms, but not for CAXII. Only the phenformin derivative 18 was found to be selective for the transmembrane CAIX and CAXII isoforms. To investigate whether the biological efficacy of the functionalized compounds is dependent on CAIX expression, canine kidney epithelial (MDCK) cells without CAIX (CAIX À ), i.e. both human and canine [37] , or MDCK cells transfected with human CAIX [37] , i.e. overexpressing CAIX (CAIX þ ), were used. Western blotting confirmed differential expression of CAIX in these cells both under normoxic and hypoxic conditions ( Supplementary  Fig. S1 ).
Chlorambucil derivatives
Chlorambucil
(4-[p-[bis(2-chloroethyl)amino]phenyl]butyric acid) is a nitrogen mustard that acts as a bifunctional alkylating agent used for decades to treat cancers originating in the blood and lymphatic system, e.g. chronic lymphocytic leukemia and lymphomas [38] . Even though reported data suggest chlorambucil efficacy to increase in an acidic microenvironment [39] , the CAIXi moiety (benzenesulfonamides) with different linkers (i.e. amide, carbamate) might allow for specific targeting of the compounds to these areas in the tumor. The six CAIXi conjugated chlorambucil derivatives (2a, 2b, 2c, 5a, 5b, and 5c, Schemes 1 and 2) lead to reduced cell viability as compared to the parental compound, which was only marginally effective ( Table 2 , Supplementary  Fig. S1 ). The therapeutic efficacy of these compounds however was not increased in the CAIX þ MDCK cells as compared with the CAIX À MDCK cells. Furthermore, none of the six compounds showed an increased efficacy upon hypoxia exposure (0.2% O 2 ). In contrast, some of the chlorambucil dual-target derivatives were less cytotoxic (i.e. higher IC 50 , Table 2 ) in CAIX expressing cells independent of oxygen levels, which contradicts the studies demonstrating an increased efficacy of chlorambucil in an acidic micromilieu [39] . All together from these results it can be concluded that the CAIXi conjugated chlorambucil derivatives do not show an increased efficacy in a CAIX or hypoxia dependent manner.
Tirapazamine derivatives
The hypoxia-activated prodrug tirapazamine (3-amino-1,2,4benzotriazine-1,4-dioxide) has been tested in several clinical trials in combination with chemo-and/or radiotherapy [40] . The cytotoxicity of tirapazamine results from activation by reductive enzymes that add an electron to the parent drug to produce a radical species that causes DNA damage. Nevertheless, no definitive conclusions regarding its clinical efficacy can be drawn since addition of tirapazamine to standard treatment (i.e. radiochemotherapy) did not result in an increased benefit in phase III clinical trials. In addition, tirapazamine treatment was often characterized by toxic side-effects, such as nausea, vomiting, and diarrhea, which limited its therapeutic gain [40] . Targeting tirapazamine towards the CAIX expressing (hypoxic) areas in tumors by conjugating tirapazamine with the benzenesulfonamide CAIXi might thereby prove a valuable approach to reduce normal tissue toxicity and increase the efficacy of the compounds (8 and 11) in CAIX expressing (hypoxic) cells. Cell viability assays ( Table 2 , Supplementary Fig. S2 ) confirmed that the parental compound was specifically effective in hypoxic cells, and more effective in CAIX À cells (IC 50 < 50 versus 95 mM, p ¼ 0.037). The CAIXi conjugated tirapazamine derivatives however abrogated the effect observed for the parental compound, both during hypoxia and normoxia, which was independent of CAIX levels ( Table 2 ).
Temozolomide derivatives
The current treatment of glioblastoma is based on radiotherapy combined with temozolomide, which has been shown to increase survival in phase III clinical trials [41] . Temozolomide is a methylating agent that spontaneously hydrolyzes to its active metabolite 3-methyl-(triazen-1-yl)imidazole-4-carboxamide (MTIC) at physiological pH [42] . The acidic extracellular pH in tumors might therefore reduce spontaneous temozolomide conversion and thereby decrease its efficacy. Inhibiting CAIX function is known to decrease extracellular acidification in vitro [24] [25], [28] , and [43] and we hypothesized that conjugating temozolomide with a sulfonamide or sulfamate moiety (15a, 15b, 15c, and 15d) will specifically target hypoxic tumors and increase temozolomide conversion and thereby its efficacy. Nevertheless, while temozolomide resulted in lower cell viability in CAIX À cells, consistent with the pH-dependent mechanism of activation, the CAIXi conjugated temozolomide derivatives 15a, 15c, and 15d were ineffective in reducing cell viability in both MDCK cell lines during normoxic and hypoxic conditions within the concentration range tested in the present study ( Table 2 , Supplementary Fig. S3 ). In contrast, 15b was similarly effective as the parental temozolomide compound ( Table 2) .
This dual-target compound was therefore investigated further in clonogenic survival assays in which the medium of the cells was acidified because of CAIX function during hypoxic conditions ( Supplementary Fig. S1 ) [44] . Temozolomide was again more effective in reducing clonogenic cell survival in the CAIX À MDCK cells as compared with the CAIX þ MDCK cells ( Fig. 1 ), similarly to its efficacy on cell viability. During hypoxia however temozolomide caused no difference in clonogenic survival as compared to normoxia, even though hypoxia is required to activate CAIX and cause extracellular acidification [43] and [45] and is therefore hypothesized to reduce temozolomide conversion and efficacy. In contrast, the CAIXi conjugated derivative 15b significantly reduced clonogenic cell survival in hypoxic versus normoxic conditions in the CAIX þ cells (surviving fraction is 46.1 ± 3.1 versus 26.1% ±7.9 during normoxia and hypoxia respectively, p < 0.05). Nevertheless, the effect of 15b on survival was not significantly different from the parental temozolomide compound. In addition, the low binding affinity of the compound (Table 1) combined with its relatively low efficacy in the CAIX þ as compared to the CAIX À cells minimizes its Table 2 Estimated IC 50 of the cytotoxic parental compounds (bold) and their CAIXi conjugated derivatives obtained with cell viability assays for MDCK CAIX À and MDCK CAIX þ cells exposed to normoxic and hypoxic conditions. 87~100  95  2b  18  98  14  92  2c  18~100  18~100  5a  8  56  8  62  5b  86  98  52  100  5c 89
a No IC 50 reached is indicated with >. Estimated IC 50 value higher than the maximum concentration included is indicated with~.
b Included concentrations for chlorambucil were 1, 10, and 100 mM. c Included concentrations for tirapazamine were 50, 100, 200, and 300 mM. d Included concentrations for temozolomide were 100, 400, 700, and 1000 mM.
potential for further development. These results furthermore suggest that temozolomide efficacy is not affected by CAIX dependent changes in extracellular pH during hypoxia. A reduction of temozolomide conversion and efficacy might require lower pH levels, i.e. pH < 6.6, which may have not been achieved in the present experiments [8] [9] , and [39] .
ATR inhibitor derivatives
Preclinical experiments have shown that Ataxia Telangiectasia and Rad3-related protein inhibitors (ATRi) reduce the DNA repair capacity resulting in enhanced cell death and decreased tumor growth when combined with either chemo-or radiotherapy [46] [47], and [48] . However ATRi are not highly tumor specific, thus targeting these compounds towards the CAIX expressing areas of a tumor might increase their therapeutic benefit. The effect on cell viability of the parental ATRi (VE-821 and VE-822) and their CAIXi conjugated derivatives (12 and 13) was tested in combination with radiotherapy to induce DNA damage where a higher radiation dose was applied to anoxic cells, since those are more radioresistant [49] and [50] . The parental ATRi and the CAIXi conjugated derivatives in combination with radiation decreased cell viability as compared to radiation only in the CAIX þ cells (p < 0.05) under both normoxic and anoxic conditions, but not in the CAIX À cells (Fig. 2) . The only exception is the derivative 13, which had no significant effect on cell viability during anoxic conditions in both cell lines as compared to radiation alone (p ¼ 0.09 and p ¼ 0.08 for CAIX À and CAIX þ cells, respectively). More importantly, the CAIXi conjugated derivative 12 was more effective than its respective parental ATRi (VE-821) in the CAIX þ (p < 0.01 during normoxia and anoxia), but not the CAIX À cells (p ¼ 0.52 and p ¼ 0.72 for normoxia and anoxia, respectively), suggesting a CAIX specific effect. In contrast, the CAIXi conjugated derivative 13 in combination with radiation was less effective in reducing cell viability than the parental compound VE-822 in CAIX þ cells (p < 0.001 and p < 0.01 during normoxic and anoxic conditions, respectively). Although radiation induced similar effects on cell viability during normoxic and anoxic conditions, the efficacy of derivative 12 did not increase further during anoxic conditions as compared to normoxic conditions, even though CAIX expression is upregulated under hypoxic conditions ( Supplementary Fig. S1 ) and these conditions are essential for CAIXi binding [43] and [45] . Although derivative 12 indeed proved to be more effective in CAIX þ than in CAIX À cells in combination with radiation, its efficacy might however not be solely dependent on binding to CAIX, which is consistent with unfavorable K i values of the compound (Table 1 ). Exposing both cell lines to ATRi without irradiation decreased cell viability of both cell lines during normoxic and anoxic conditions, although this effect appeared to be slightly more pronounced in the CAIX À cells ( Supplementary  Fig. S5 ). Differences in ATRi response between the cell lines when combined with radiation might be explained by a lower number of cells in the resistant S-phase of the cell cycle [51] , or by a decreased DNA repair capacity in cells with lower intracellular pH [52] [53] , and [54] , i.e. those that do not express CAIX. This may also explain the difference in sensitivity to cytotoxic drugs between both cell lines, although further investigations are required to prove this Relative cell viability (%) in MDCK CAIX À and CAIX þ cells exposed to ATR inhibitors (VE-821 and VE-822) or the CAIXi conjugated derivatives (12 and 13) in combination with radiation during normoxia (21% O 2 ) and anoxia ( 0.02% O 2 ). Normoxic cells were irradiated with 2 Gy and anoxic cells with 4 Gy to induce similar effects on cell viability. Cells were exposed to 500 nM VE-821 and 12, and to 50 nM VE-822 and 13. Average ± SEM of three independent biological repeats is shown. Asterisks indicate statistical significance (*p < 0.05; **p < 0.01; ***p < 0.001). causal relationship.
Phenformin derivatives
Phenformin (1-(diaminomethylidene)-2-(2-phenylethyl)guanidine) is a drug used to treat diabetes, but was withdrawn from the North-American market in the 1970s by the Food and Drug Administration (FDA) due to a high risk of developing lactic acidosis [55] . Treating patients with a similar but less potent drug metformin was found to be associated with a decrease in cancer incidence and an increased life span of cancer patients [56] . The repurposing of these compounds as anti-cancer agents is therefore being investigated where phenformin is found to be more lipophilic, thereby requiring less active transport than metformin [57] . The proposed mechanism of action of phenformin is its ability to inhibit mitochondrial respiration, which will consequently result in a decreased ATP production, thereby reducing tumor cell growth and improving tumor oxygenation as a result of decreased oxygen consumption [58] and [59] . Conjugating phenformin with CAIXi might make the drug more tumor-specific leading to reduced normal tissue toxicity. Since tumor cells are more sensitive to phenformin treatment due to their altered energy metabolism, human colorectal HCT116 cells, with or without CAIX knockdown [24] and [28] were used to study the effect of phenformin and its CAIXi conjugated derivative 18 on mitochondrial respiration. Western blotting confirms low expression of CAIX in CAIX KD cells under hypoxic conditions as compared with control cells ( Supplementary Fig. S1B ). As expected, CAIX levels were low in both cell lines under normoxic conditions. Phenformin significantly reduced Oxygen Consumption Rate (OCR) in both cell lines (p < 0.05), independent of CAIX expression levels (Fig. 3) . In contrast, the CAIXi conjugated derivative 18 was ineffective in reducing OCR, even when a fourfold higher concentration was used.
Conclusion
Overall our hypothesis that newly designed dual-target drugs are more selective for CAIX expressing cells and are able to modulate their own efficacy by inhibiting CAIX function was not confirmed. Of all derivatives included, only one (i.e. the ATRi derivative 12) proved more effective than its parental compound when combined with irradiation in CAIX þ cells versus CAIX À cells. Nevertheless, the effect of this compound may not only be related to binding of the compound to CAIX due to limited binding affinity and the lack of further increase in its efficacy under hypoxic conditions. The rest of the derivatives included in this study did not show an increased efficacy in CAIX þ versus CAIX À cells, or an efficacy that depended on oxygen levels, i.e. hypoxia versus normoxia. Nevertheless, since the parental compounds proved effective in these experiments the conjugation of the CAIXi moiety with the cytotoxic compounds may have caused conformational changes, thereby altering the compounds efficacy. In addition, these conformational changes may have also limited the binding of the CAIXi moiety (sulfonamide, sulfamide or aminoxysulfonamide) into the Zn 2þ containing active pocket of CAIX, which explains the lack of CAIX specificity and binding affinity for human CAs (Table 1) of the compounds. Alternative strategies to target the CAIX expressing cells in a tumor, e.g. antibody targeting or an increased number of CAIXi conjugated molecules [60] , might therefore be more promising options to pursue in the future.
Experimental section
4.1. Chemistry
General
Unless otherwise specified, reagents and solvents were of commercial quality and were used without further purification. All reactions were carried out under an inert atmosphere of nitrogen. TLC analyses were performed on silica gel 60 F 254 plates (Merck Art.1.05554). Spots were visualized under 254 nm UV illumination, or by ninhydrin solution spraying. Melting points (mp) were determined on a Büchi Melting Point 510 and are uncorrected. 1 H and 13 C NMR spectra were recorded on Bruker DRX-400 spectrometer using DMSO-d 6 as a solvent and tetramethylsilane as an internal standard. For 1 H NMR spectra, chemical shifts are expressed in d (ppm) downfield from tetramethylsilane, and coupling constants (J) are expressed in Hertz. Electron Ionization mass spectra were recorded in positive or negative mode on a Waters MicroMass ZQ. All compounds that were tested in the biological assays were analyzed by High-resolution ESI mass spectra (HRMS) using on a Q-ToF I mass spectrometer fitted with an electrospray ion source in order to confirm the purity of >95%.
4-(4-(Bis(2-chloroethyl)amino)phenyl)butanoyl chloride (1)
Oxalyl chloride (32.8 mmol, 2.0 equiv.) was added slowly over a period of 1.0 h at 5e10 C to a stirred solution of chlorambucil (16.4 mmol, 1.0 equiv.) in DCM (25.0 mL, 5.0 vol) and a catalytic amount of N, N-dimethylformamide. The reaction mixture was stirred at ambient temperature for 2e3 h, after which excess oxalyl chloride and DCM were removed under reduced pressure. The chlorambucil acid chloride that was obtained was a pale green solid in quantitative yield, which was used as such for the synthesis of Compounds 2aec.
4-(4-(Bis(2-chloroethyl)amino)phenyl)butan-1-ol (3)
Compound 1 (15.5 mmol, 1.0 equiv.) was dissolved in DCM (125 mL) and methanol (75 mL, 3 vol) was slowly added over a period of 1 h at 15e20 C. The reaction mixture was stirred at ambient temperature for 2 h. The reaction mixture was concentrated and the residue was dissolved in ethyl acetate (125 mL, 5 vol) and washed successively with a 5% aq. NaHCO 3 . Evaporation of the solvent under reduced pressure resulted in the chlorambucil methyl ester (16.4 mmol, 1.0 equiv.) in 95% yield as a light brown oil, which was added to a suspension of lithium aluminium hydride (32.8 mmol, 2 equiv.) in anhydrous THF (100 mL, 4 vol) at 0e5 C for a period of 1 h. The reaction mixture was thereafter allowed to stir at ambient temperature for 2e3 h. Next, the reaction mixture was cooled to 0e5 C and quenched slowly with ethyl acetate (250 mL, Fig. 3 . Oxygen Consumption Rate (OCR) of HCT116 cells with CAIX (shSCR) or without CAIX expression (shCAIX) exposed to phenformin or the CAIXi conjugated derivative 18. OCR was normalized to baseline OCR levels before compound injection. Average ± SEM of four independent biological repeats is shown. Asterisks indicate statistical significance (*p < 0.05). 10 vol) followed by water (100 mL, 4 vol). The reaction mixture was filtered through celite and ethyl acetate (50 mL, 2 vol) was used to wash the celite bed. The organic layer was washed with water (100 mL, 4 vol), dried over anhydrous Na 2 SO 4 , and filtered. Evaporation of the solvent under reduced pressure resulted in 99% yield of the crude alcohol as a pale yellow oil, which was used in the next step.
4-(4-(Bis(2-chloroethyl)amino)phenyl)butyl carbonochloridate (4)
DMF (1.4 g) and sodium carbonate (75.79 mmol, 1.1 equiv.) were added to a solution of triphosgene (37.89 mmol, 0.55 equiv.) in toluene (300 mL, 15 vol) at ambient temperature. The reaction mixture was cooled to 0e5 C and maintained at the same temperature for 30 min. Next, a solution of 3 (68.9 mmol, 1.0 equiv.) in toluene (100 mL, 5 vol) was added to the stirred reaction mixture at 0e5 C during 30 min. This reaction mixture was stirred for 4e5 h at room temperature. The reaction mixture was filtered thereafter and the solid was washed with toluene (100 mL, 5 vol). Evaporation of the solvent under reduced pressure resulted in the chloroformate 4 with a 64% yield as a yellow viscous liquid, which was used for the synthesis of carbamates (compounds 5aec).
General procedure for the preparation of compounds (2aec and 5aec)
To a solution of aminoalkylbenzene sulfonamide (1.0 equiv.) in acetonitrile (225 mL, 15 vol) and N,N-diisopropylethylamine (2.5 equiv.) a solution of compound 1 (2aec) or compound 4 (5aec) (1.0 equiv.) in acetonitrile (75 mL, 5 vol) was added over a period of 1 h and stirred overnight at ambient temperature. After completion, the reaction mixture was concentrated and the residue obtained was dissolved in ethyl acetate (150 mL, 10 vol). The organic layer was successively washed with 2 N HCl solution (100 mL Â 2) in water, dried over anhydrous Na 2 SO 4 , and filtered. After evaporation of the solvent under reduced pressure a pale yellow solid was obtained as a crude product. This crude product was purified with column chromatography using a silica gel (40% ethyl acetate in hexane) to obtain compound 2aec and 5aec in a 51e87% yield. 4.1.6. General procedure for amination of 3-Chlorobenzotriazine-1,4-di-N-oxides (7 and 10) 4-(2-Aminoethyl) benzene sulfonamide (8.25 mmol, 3.0 equiv.) was added to a stirring solution of 3 chlorobenzotriazine-1,4-di-Noxide (2.75 mmol, 1.0 equiv.) in dimethoxyethane (30 mL) and the mixture was stirred overnight at reflux temperature. The next day mixture was cooled to room temperature and concentrated under vacuum, after which the residue was dissolved in ammonium hydroxide solution and extracted with ethyl acetate. The organic layer was dried over Na 2 SO 4 , filtered and concentrated under vacuum. The residue was purified by chromatography using a silica gel with methylene chloride-methanol 98:2 v-v as an eluent to obtain the expected compound as a yellow powder with an 85e94% yield.
General procedure for oxidation (8 and 11)
Hydrogen peroxide (12.9 mmol, 10 equiv.) was added dropwise to a stirred solution of trifluoroacetic anhydride (12.9 mmol, 10 equiv.) in DCM at 0 C. This reaction mixture was stirred at 0 C for 5 min, warmed to room temperature for 10 min, and cooled to 5 C. Next, the mixture was added to a stirred solution of mono oxide (1.29 mmol, 1.0 equiv.) in DCM at 0 C and stirred at room temperature for 2e3 days. The reaction mixture was carefully diluted with water and basified with aqueous NH 4 OH and extracted with CHCl 3 . The organic fraction was dried over anhydrous Na 2 SO 4 , filtered and evaporated to obtain the residue. This residue was purified by chromatography using a silica gel with methylene chloride-methanol 98:2 v-v as an eluent to obtain the expected compound as an orange red powder with a 46e96% yield.
General procedure for synthesis of ATRi derivatives (12 and 13)
A solution of VE-821 or VE-822 (0.54 mmol, 1.0 equiv.) and triethylamine (1.62 mmol, 3.0 equiv.) in 10 mL of methylene chloride was added to a mixture of chlorosulfonyl isocyanate (0.68 mmol, 1.2 equiv.) and tert-butanol (0.648 mmol, 1.2 equiv.) in 2 mL of methylene chloride. The mixture was stirred at room temperature for 1.0 h, diluted with ethyl acetate, and washed with water. The organic layer was then dried over anhydrous Na 2 SO 4 , filtered and concentrated under vacuum. The residue was purified by chromatography with a silica gel and methylene chloridemethanol 98:2 as an eluent. This intermediate was thereafter diluted in a solution of trifluoro acetic acid in methylene chloride (20% vol.) and stirred at room temperature for 6 h. Next, the mixture was concentrated under vacuum and co-evaporated with diethyl ether multiple times to obtain the expected compound with a 58e65% yield. (m, 2H), 1.76e1.65 (m, 2H); 13 Compound 7 was synthesized from 6 by a general amination method and resulted in a yellow solid with a yield of 94%. mp: (dd, J ¼ 6.2, 2H); 13 Compound 10 was synthesized from 9 by using a general amination method, which resulted in a yellow solid with a 85% yield. (11) Compound 11 was synthesized from 10 by using a general oxidation method resulting in an orange red solid with a yield of 46%. mp: 218e220 C; 1 Compound 12 was synthesized from commercially purchased VE-821 by using the general procedure described above, which resulted in a yellow solid with an overall yield of 58%. mp: Compound 13 was synthesized from commercially purchased VE-822 by using the general procedure described above, which resulted in a yellow solid with an overall yield of 65%. mp: 242e244 C; 1 Compound 15c was synthesized from 14 by reacting it with 4-(aminomethyl) benzene sulfonamide hydrochloride using the general procedure for synthesizing temozolomide derivatives described above. This reaction resulted in a white solid with a yield of 88%. mp: 185e187 C; 1 
CA inhibition assays
To measure the CA-catalyzed CO 2 hydration activity an Applied Photophysics stopped-flow instrument was used [61] . To maintain ionic strength Na 2 SO 4 (20 mM) was used with HEPES (20 mM, pH 7.5) as a buffer and Phenol red (0.2 mM) as an indicator working at the maximum absorbance of 557 nm, which was used to follow the initial rates of the CA-catalyzed CO 2 hydration for a duration of 10e100 s. To determine the kinetic parameters and inhibition constants varying CO 2 concentrations were included (1.7e17 mM). Initial velocity was assayed with at least six traces of the initial 5e10% of the reaction for each compound. Compounds were dissolved in distilled-deionized water (0.01 nM). The combined enzyme solutions and compounds were incubated for 15 min at room temperature to allow for the E-I complex formation prior to measurements. The nonlinear least-squares method of PRISM 3 was used to estimate the inhibition constants and the mean of three independent estimations is reported. The CA isoforms included are recombinant proteins obtained in house.
Biological assays
Cells
All cell lines used were cultured in DMEM supplemented with 10% fetal bovine serum. Canine kidney epithelial MDCK cells overexpressing human CAIX (CAIX þ ) or a scrambled control vector (CAIX À ) have been described before [37] and [44] . The HCT116 constitutive CAIX knockdown cell line and its scrambled control have also been described before and were kindly provided by Professor Adrien Harris (Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe hospital, Oxford, UK) [24] [28], and [62] . Cells were exposed to hypoxic or anoxic conditions in a hypoxic chamber (MACS VA500 microaerophilic workstation, Don Whitley Scientific, UK) with 0.2 or 0.02% O 2 , respectively, and 5% CO 2 and residual N 2 to upregulate and activate CAIX. Normoxic cells were grown in normal incubators with 21% O 2 , 5% CO 2 at 37 C.
Cell viability assays
The efficacy of the cytotoxic derivatives was compared to their respective parental compounds in cell viability assays using ala-marBlue ® (Invitrogen). In short, MDCK cells were seeded in 96-well plates and allowed to attach overnight. The next day plates were exposed to hypoxia and DMEM was replaced with pre-incubated hypoxic DMEM. In contrast, testing the ATRi was performed in anoxic conditions to decrease the radiosensitivity of the cells. In parallel normoxic 96-well plates were incubated in normal incubators with 21% O 2 and 5% CO 2 . Compounds were dissolved in DMSO (0.5%, Sigma-Aldrich) and final concentrations were made with pre-incubated hypoxic or normoxic DMEM and added to the wells after 24 h of exposure. To test the ATR inhibitors cells were exposed to the compounds 1 h prior to irradiation and the 96-well plates were irradiated (225 kV Philips X-ray tube) with 2 Gy (normoxia) or 4 Gy (anoxia). Cells were exposed to compounds for a total of 2 h for chlorambucil and tirapazamine, or 72 h for temozolomide and the ATR inhibitors, after which medium was washed off and replaced with fresh medium. For chlorambucil, tirapazamine, and ATR inhibitor derivatives cells were allowed to grow for an additional 72 h under normoxic conditions prior to measurement, whereas cells exposed to temozolomide derivatives remained in hypoxic conditions prior to measurement. Cells were allowed to convert alamarBlue ® for 2 h during normoxic conditions, which corresponds with their metabolic function and is a measure for cell viability.
Clonogenic assays
Clonogenic survival of MDCK cells was determined with high cell numbers to allow for CAIX-dependent extracellular acidification [44] . These cells were exposed to temozolomide or 15b for 24 h during normoxic or hypoxic conditions after which cells were trypsinized and reseeded in triplicate with known cell numbers. Cells were allowed to grow for 7 days to form colonies that were quantified after staining and fixation with 0.4% methylene blue in 70% ethanol. Surviving fraction was normalized to vehicle (0.5% DMSO).
Basal respiration measurements
Oxygen Consumption Rates (OCR) were determined using the Seahorse XF96 extracellular Flux analyzer (Agilent Technologies). Cells were seeded in a XF96 cell plate with normal growth medium at an optimized cell density of 1.5 Â 10 4 cells/well. Plates were placed in a 5% CO 2 incubator at 37 C in order to let the cells attach. Subsequently cells were incubated for 18 h under hypoxic conditions (0.2% O 2 ). Culture medium was exchanged with DMEM containing 25 mM D-glucose, 4 mM L-glutamine and 1 mM sodiumpyruvate (GIBCO, Thermo Fisher) 60 min prior to the assay and plates were placed in a CO 2 -free incubator at 37 C. Prior to the first injection, baseline OCR was determined using a mixing period of 5 min and a measurement period of 3 min followed by 3 loops of mixing and measuring for 3 min each. Medium containing vehicle (PBS, Lonza), Phenformin Hydrochloride (Sigma-Aldrich), or the CAIXi conjugated phenformin derivative 18 were injected followed by several mixing and measurements cycles. Subsequently cells were washed with PBS and lysed in a 0.05% SDS (Sigma-Aldrich) solution. Protein quantification for normalization purposes was performed using Pierce™ BCA Protein Assay Kit (Thermo Fisher).
Western blot
To validate CAIX expression in the genetically modified cell lines protein immunoblotting was performed after 24 h of hypoxia exposure (0.2% O 2 ) as described previously [43] . Primary antibodies used included the anti-CAIX M75 antibody (kindly provided by Professor Silvia Pastorekova, Institute of Virology, Slovak Academy of Science, Slovak Republic), and anti-b-actin (MP Biomedicals, #691001) as a reference protein.
Statistical analyses
GraphPad Prism (version 5.03) was used for all statistical analyses. For the cytotoxic compounds IC 50 values were estimated with the curve of the log(inhibitor) vs. normalized response (Variable slope). Means between groups were compared using unpaired ttests, where p < 0.05 indicated statistical significance.
